Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
  • A61K38/46—Hydrolases (3)
  • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
  • A61K38/482—Serine endopeptidases (3.4.21)
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K20/00—Accessory food factors for animal feeding-stuffs
  • A23K20/10—Organic substances
  • A23K20/189—Enzymes
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K50/00—Feeding-stuffs specially adapted for particular animals
  • A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents

Definitions

• Gao et al. (Fish Shellfish Immunol. 2016 Jul;54:573-9; doi: 10.1016/j.fsi.2016.05.013) reports Lactobacillus plantarum lipoteichoic acid has potential as a therapeutic agent against V. anguillarum-caused vibriosis in fish.
• Ringo et al. (Front. Microbiol. 9: 1818; doi: 10.3389/fmicb.2018.01818) reports on lactic acid bacteria in finfish and states that the Gl tract in fish is one of the most important interfaces with the environment exposed to potential pathogens, it is of importance to evaluate the presence of beneficial bacteria such as lactic acid bacteria in the Gl tract, as autochthonous bacteria rapidly colonize the digestive tract at early developmental larval stages of finfish. The authors thus conclude that that lactic acid bacteria administration results in beneficial effects such as disease resistance and weight gain in finfish aquaculture.
• the clue of the present invention is to improve the balance between beneficial and deleterious bacteria in the gastrointestinal tract of aquatic species by feeding aquatic species with a composition comprising a protease, rather than feeding aquatic species with beneficial bacteria, e.g. Lactobacillus species.
• the present invention does not exclude feeding aquatic species in addition to a composition comprising a protease as described herein with one or more probiotic bacteria.
• the surprise that came with the present invention is the finding that the level beneficial bacteria can be increased by feeding aquatic species with a composition comprising a protease, rather than merely feeding aquatic species with beneficial bacteria. This effect could not have been suspected, let alone expected.
• the present inventors took the non-obvious action and fed aquatic species with a protease, thereby observing and proofing that the level of beneficial bacteria is enhanced, while the level of deleterious bacteria is decreased, i.e., the balance between the level of beneficial and deleterious bacteria in the gut of aquatic species is improved.
• the present invention relates to the use of a composition comprising a protease for improving the balance of beneficial and deleterious bacteria in the gastrointestinal tract of aquatic species. Also, the present invention relates to a method for improving the balance of beneficial and deleterious bacteria in the gastrointestinal tract of aqua species, comprising feeding aquatic species with a composition comprising a protease.
• the present invention relates to a method of culturing an aquaculture of an aquatic species, comprising improving the balance of beneficial and deleterious bacteria in the gastrointestinal tract of said aquatic species by the means of a composition comprising a protease.
• composition further comprises one or more probiotic bacteria, preferably lactic acid bacteria, e.g. Lactobacillus spp.
• polypeptide comprising the polypeptide of (a) or (b) and a N-terminal and/or C-terminal His-tag and/or HQ-tag;
• polypeptide comprising the polypeptide of (a) or (b) and a N-terminal and/or C-terminal extension of up to 10 amino acids, e.g. 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids; or
• Example 1 Effect of different enzymes supplement on gut health in white shrimp
• Enzyme products from DSM, Ronozyme® Hiphos, Ronozyme® ProAct (SEQ ID NO: 1), Ronozyme® VP and HyD or ProAct 360 (SEQ ID NO: 4) can be used as feed additive for this trial.
• ProAct SEQ ID NO: 1 was used in this trial.
• Pacific white shrimp (Litopenaeus vannamei) size 2-3 g were used for this trial. They were cultured from post larvae at AQST. Post larvae provided from a commercial shrimp farm in Thailand, and the pathogenic free status including WSSV, YHV, IHHNV, TSV, IMNV, AHPND and EHP will be checked by PCR in order to guarantee the shrimp health. Initially, shrimp were transferred to 390-L tank at salinity 15 ppt for 2 days prior to start the experiment.
• Gut microbiota composition from shrimp tissue samples from DSM was analyzed according to the following scheme ( Figure 2). Intestine microbiome analysis was carried out according to the methodology depicted in Figure 3.
• Example 2 Microbiome analysis in hepatopancreas of Pacific white shrimp (Litopenaeus vannamei) fed the experimental diets for 8 weeks
• negative control stands for a 15% fish meal diet
• positive control stands for a 25% fishmeal diet, both negative and positive control are without protease
• ProAct stands for the protease added to the fishmeal diet.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Veterinary Medicine (AREA)
• Polymers & Plastics (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Chemical & Material Sciences (AREA)
• Food Science & Technology (AREA)
• Epidemiology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Immunology (AREA)
• Animal Husbandry (AREA)
• Gastroenterology & Hepatology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Zoology (AREA)
• Insects & Arthropods (AREA)
• Marine Sciences & Fisheries (AREA)
• Birds (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Enzymes And Modification Thereof (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=83689049

Family Applications (1)

Country Status (3)

Families Citing this family (1)

Family Cites Families (3)

• 2023
  • 2023-08-29 WO PCT/EP2023/073601 patent/WO2024047009A1/en not_active Ceased
  • 2023-08-29 EP EP23762415.0A patent/EP4580656A1/de active Pending
• 2025
  • 2025-02-26 CL CL2025000521A patent/CL2025000521A1/es unknown

Also Published As

Similar Documents

Legal Events